Synthetic Hormones Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Amino Acid Derivatives, Peptide Hormone, Steroid Hormones), By Route of Administration (Intravenous, Nasal, Oral, Suppository, Topical), By Application (Growth Hormone Deficiency, Male Hypogonadism, Menopause, Thyroid Hormone Deficiency), By End User (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), By Region, and Competition, 2020-2030F

Market Overview

Global Synthetic Hormones Market was valued at USD 595.65 Million in 2024 and is anticipated to witness an robust growth in the forecast period with a CAGR of 12.15% through 2030. Synthetic hormones are artificially created or manufactured versions of naturally occurring hormones in the human body. These synthetic hormones have the same chemical structure and function as the hormones produced by the endocrine glands, but they are produced in laboratories rather than within the body. Synthetic hormones are used for various medical purposes, including hormone replacement therapy (HRT), contraception, and the treatment of hormone-related medical conditions. Synthetic hormones are prescribed by healthcare providers to address hormonal imbalances, manage symptoms of hormone-related conditions, and provide contraception. They are used to treat a wide range of conditions, including menopause symptoms, hypothyroidism, hormone-related cancers, and fertility control. Synthetic hormones are used in various forms of contraception, including birth control pills, patches, injections, and intrauterine devices (IUDs). These hormones prevent pregnancy by inhibiting ovulation, thickening cervical mucus, and altering the uterine lining to make it less receptive to a fertilized egg. Synthetic hormones are used to manage and treat hormone-related medical conditions such as hypothyroidism, hyperthyroidism, hormone-dependent cancers (e.g., breast cancer, prostate cancer), and disorders like polycystic ovary syndrome (PCOS) and endometriosis. The world's population is aging, particularly in developed countries. As people age, they may experience hormonal imbalances and conditions that require hormone replacement therapy, contributing to the demand for synthetic hormones. The increasing incidence of hormone-related disorders such as hypothyroidism, diabetes, and hormone-dependent cancers is driving the demand for synthetic hormones for therapeutic purposes. Innovations in drug delivery technologies, including transdermal patches, implants, and long acting injectables, have improved the ease of administering synthetic hormones, enhancing patient compliance and convenience. Growing awareness among healthcare professionals and patients about the importance of hormone management and the availability of synthetic hormone therapies is boosting demand.

Key Market Drivers

Rising Prevalence of Hormonal Disorders

The increasing prevalence of hormonal disorders is one of the most significant factors driving the expansion of the global synthetic hormones market. Hormonal imbalances can affect multiple physiological functions, leading to chronic diseases, reproductive health issues, metabolic disorders, and growth abnormalities. Globally, an estimated 60 to 80 million couples face infertility challenges, driving demand for assisted reproductive technologies and hormone-based treatments. Simultaneously, developing nations experience a significant gap in contraceptive access, creating opportunities for expanded family planning solutions. The lack of safe reproductive healthcare contributes to 115,000 to 204,000 fatalities annually due to unsafe abortion practices, underscoring the urgent need for improved healthcare infrastructure and strategic investments in reproductive health services. As the number of patients diagnosed with these conditions continues to grow, the demand for synthetic hormone therapies rises correspondingly. Hormonal disorders such as hypothyroidism, adrenal insufficiency, and menopause-related complications require long-term hormone replacement therapy (HRT). Synthetic hormones like levothyroxine (for thyroid disorders), estrogen and progesterone (for menopause), and corticosteroids (for adrenal gland deficiencies) are essential for managing these conditions. The global population of postmenopausal women is expanding rapidly. In 2021, women aged 50 and older comprised 26% of the global female population, up from 22% a decade earlier. This demographic shift is further amplified by increasing life expectancy—in 2019, a 60-year-old woman could expect to live significantly longer on average. These trends are driving growing demand for hormone replacement therapies (HRT), menopause management solutions, and age-related healthcare innovations, creating substantial opportunities in the pharmaceutical and healthcare sectors. With a growing aging population, cases of menopause, osteoporosis, and testosterone deficiency are increasing, leading to a higher adoption of synthetic hormones. Expanding insurance coverage and improved healthcare accessibility have made HRT more affordable and widely available, further stimulating market growth.

Diabetes, particularly type 1 diabetes, is a major hormonal disorder characterized by insulin deficiency. Diabetes mellitus (DM) impacts over 425 million individuals worldwide, with a global prevalence of 8.5%. Notably, only 5-10% of cases are classified as Type 1 DM. The condition contributes to approximately 5.2 million deaths annually, translating to a mortality rate of 82.4 per 100,000 individuals. These figures underscore the significant health and economic burden of diabetes, highlighting the urgent need for advanced therapeutic solutions and strategic healthcare investments. The rising global diabetes burden is fueling the demand for synthetic insulin therapies, a critical segment of the synthetic hormones market. According to the International Diabetes Federation (IDF), diabetes cases are expected to rise significantly in the coming decades, ensuring sustained demand for insulin-based treatments. Pharmaceutical companies are actively investing in advanced insulin formulations and delivery systems, such as long-acting insulin analogs and smart insulin pens, to cater to this expanding market. Infertility is a growing concern worldwide due to lifestyle changes, stress, delayed pregnancies, and environmental factors. This has led to an increase in assisted reproductive technologies (ART) such as in-vitro fertilization (IVF), intrauterine insemination (IUI), and ovulation induction therapies. Synthetic hormones such as gonadotropins (FSH, LH, hCG), progesterone, and estrogen play a vital role in stimulating ovulation, maintaining pregnancy, and improving fertility outcomes. The demand for fertility treatments has surged, particularly in developed markets like the U.S., Europe, and emerging economies such as India and China, where ART procedures are gaining traction.

Rising Infertility Rates

The rising global infertility rates have become a significant driver of the synthetic hormones market, as hormone-based treatments play a critical role in fertility management, assisted reproductive technologies (ART), and hormone therapy for conception support. With an increasing number of individuals and couples facing reproductive challenges, the demand for synthetic hormones such as gonadotropins, progesterone, estrogen, and human chorionic gonadotropin (hCG) is growing exponentially. Infertility has emerged as a global health concern, with statistics indicating a rising number of cases due to lifestyle changes, delayed pregnancies, and environmental factors. Approximately 17.5% of the global adult population—equivalent to one in six individuals—faces infertility, underscoring the critical need for expanded access to cost-effective, high-quality fertility treatments. New data reveals minimal regional disparities in infertility rates, with prevalence remaining consistent across high-, middle-, and low-income countries. Lifetime infertility rates stand at 17.8% in high-income nations and 16.5% in low- and middle-income regions, reinforcing the fact that infertility is a universal healthcare challenge requiring strategic investment in reproductive health solutions. This has directly led to increased reliance on hormonal therapies to stimulate ovulation, regulate menstrual cycles, and support pregnancy maintenance. Many women suffer from polycystic ovary syndrome (PCOS), endometriosis, and ovarian dysfunction, all of which contribute to infertility and require synthetic hormone treatments. Decreasing testosterone levels, low sperm count, and poor sperm motility are also fueling the demand for hormone-based fertility treatments, including synthetic gonadotropins and testosterone therapies. The global assisted reproductive technology (ART) market, which includes in-vitro fertilization (IVF), intrauterine insemination (IUI), and ovulation induction therapies, has witnessed significant growth.  Synthetic follicle-stimulating hormone (FSH) and luteinizing hormone (LH) are commonly used in fertility treatments to stimulate egg production. Human chorionic gonadotropin (hCG) is administered to trigger the final maturation of eggs before egg retrieval in IVF cycles. Progesterone therapy is essential for maintaining the uterine lining and preventing miscarriages in early pregnancy. With global fertility clinics expanding and increasing access to ART treatments, the demand for synthetic hormones continues to rise, creating a lucrative market for pharmaceutical companies. Modern lifestyles have contributed to an increase in infertility rates, Many individuals and couples are choosing to have children later in life, increasing the likelihood of age-related fertility decline, which necessitates hormone-based interventions.

High-stress levels and demanding work environments have been linked to hormonal imbalances that affect fertility, increasing the need for synthetic hormone therapies. In 2022, one in eight people globally was affected by obesity, highlighting its growing impact on public health. Since 1990, adult obesity rates have more than doubled, while adolescent obesity has increased fourfold. That year, 2.5 billion adults (18+) were classified as overweight, with 890 million diagnosed with obesity. Additionally, 43% of adults were overweight, and 16% were living with obesity, underscoring the widespread prevalence of weight-related health concerns. Alarmingly, 37 million children under the age of five were overweight, signaling an urgent need for preventive healthcare strategies, targeted interventions, and innovations in weight management solutions. Unhealthy lifestyles, obesity, and poor nutrition can negatively impact reproductive health, leading to a higher reliance on hormone-based fertility treatments. As these lifestyle trends continue, the global demand for hormone-based infertility treatments is expected to grow, further driving the expansion of the synthetic hormones market.

Download Free Sample Report

Key Market Challenges

Competition from Bioidentical Hormones

Some consumers prefer bioidentical hormones because they believe they are more "natural" and are less likely to cause adverse effects. This preference can lead to a shift in demand away from traditional synthetic hormones. Bioidentical hormones are often marketed as having fewer side effects and safety concerns compared to traditional synthetic hormones. This perception can influence patients' and healthcare providers' choices when selecting hormone replacement therapies. Bioidentical hormones are often compounded on an individual basis by compounding pharmacies to meet a patient's specific needs. This customization can make bioidentical hormones more attractive to patients seeking personalized treatment regimens. Bioidentical hormone products are sometimes marketed aggressively, highlighting their perceived benefits over traditional synthetic hormones. This marketing can sway consumer and prescriber preferences. Bioidentical hormones may face different regulatory oversight compared to synthetic hormones. In some regions, they may be classified as dietary supplements rather than pharmaceuticals, potentially leading to variations in quality and safety standards. There is an ongoing scientific debate about the safety and efficacy of bioidentical hormones compared to traditional synthetic hormones. This debate can create confusion among patients and healthcare providers. The compounding of bioidentical hormones can result in variability in the formulations and dosages of these products. This variability can make it challenging to establish consistent treatment protocols. Insurance coverage for bioidentical hormones may be less common than for traditional synthetic hormones, leading to higher out-of-pocket costs for patients. Bioidentical hormones may not have as extensive a body of clinical research and data supporting their safety and efficacy as traditional synthetic hormones. This can affect prescriber confidence in their use.

Patent Expirations

Once a patent expires, generic drug manufacturers can produce and market generic versions of the formerly patented synthetic hormone drug. Generic competition typically leads to lower drug prices, which can reduce the market share and profitability of the brand-name synthetic hormone. With the entry of generic competitors, prices for the synthetic hormone drug can decline significantly. This can impact the revenue generated by the drug, especially for the original manufacturer. As generic versions become available, they may gain a substantial share of the market, especially if they are priced significantly lower than the brand-name drug. This can lead to a reduced market share for the original drug. Patent expirations often result in a decline in the revenue generated by the brand-name synthetic hormone drug. This can impact the financial health of the pharmaceutical company that developed and marketed the drug. The entry of generic competitors can intensify competition within the market. Pharmaceutical companies may need to invest more in marketing and promotion to maintain market share. Before patent expiration, the original manufacturer of the synthetic hormone drug typically holds a monopoly on its sale. After patent expiration, multiple manufacturers can produce the drug, reducing the original company's exclusive control over the market. The influx of generic versions of the synthetic hormone drug can saturate the market, making it more challenging for all manufacturers to maintain profitability.

Key Market Trends

Focus on Personalized Medicine

 Personalized medicine allows healthcare providers to select the most appropriate synthetic hormone therapy and dosage for each patient based on their specific hormonal imbalances, genetics, and response to treatment. This can lead to more effective and efficient treatment outcomes. By considering individual patient factors, including genetic variations and susceptibility to side effects, personalized medicine aims to minimize adverse reactions to synthetic hormones, improving patient safety and compliance. For conditions such as menopause or hypogonadism, personalized medicine enables the customization of hormone replacement therapy (HRT) to meet the unique needs of each patient. This can result in more precise symptom relief and hormonal balance. Personalized medicine may involve genetic testing to identify individuals at higher risk for hormone-related disorders or cancers. Such insights can lead to early intervention and prevention strategies. Continuous monitoring of patients' response to synthetic hormone therapies, including hormonal levels and symptom improvement, allows for real-time adjustments to treatment plans, ensuring optimal outcomes. Genetic testing and the identification of biomarkers can help identify patients who are most likely to benefit from specific synthetic hormone treatments, improving the cost-effectiveness of therapies. In the context of hormone-related cancers (e.g., breast, prostate), personalized medicine can guide treatment decisions, including the use of hormone therapies and targeted therapies tailored to the individual's cancer genetics. Personalized medicine aims to reduce overtreatment by avoiding unnecessary hormonal interventions for individuals who do not require them, thus minimizing potential risks and costs.

Segmental Insights

Product Insights

In 2024, The steroid hormones segment is emerging as the fastest-growing category in the global synthetic hormones market, driven by rising demand across multiple therapeutic areas, including reproductive health, endocrinology, oncology, and metabolic disorders. With continuous advancements in pharmaceutical formulations, increasing adoption of hormone replacement therapies (HRT), and expanding applications in personalized medicine, the market for synthetic steroid hormones is experiencing significant growth momentum. Steroid hormones play a crucial role in managing various hormone-related disorders, contributing to their strong market growth. These hormones include corticosteroids, estrogens, progestins, and androgens, Increasing cases of adrenal insufficiency, hypogonadism, and estrogen or testosterone deficiencies are driving the demand for synthetic steroid hormones. Oral contraceptives, menopausal hormone therapy, and infertility treatments are major contributors to market expansion. Conditions such as Cushing’s syndrome, Addison’s disease, and polycystic ovary syndrome (PCOS) require steroid hormone-based treatments. The growing patient base and rising healthcare awareness are accelerating the adoption of synthetic steroid hormone therapies, fueling market expansion.

Route of Administration Insights

In 2024, the Global Synthetic Hormones Market largest share was held by Oral segment and is predicted to continue expanding over the coming years.  Many patients prefer oral medications because they are easy to take, convenient, and do not require injections or other invasive methods. Convenience and patient comfort play a crucial role in the choice of administration route. Oral synthetic hormone medications are widely available and are commonly prescribed by healthcare providers. They are accessible in various forms, including tablets and capsules. Oral medications often offer dosing flexibility. Healthcare providers can adjust the dose as needed for individual patients, which is important in hormone replacement therapy and other hormone-related treatments. Pharmaceutical companies continue to develop and improve oral formulations of synthetic hormones, enhancing their effectiveness and patient compliance.

End-User Insights

In 2024, the Global Synthetic Hormones Market largest share was held by Retail Pharmacies segment in the forecast period and is predicted to continue expanding over the coming years.  Retail pharmacies are widely distributed and easily accessible to the general population. Patients can visit their local retail pharmacies to fill prescriptions for synthetic hormones, making it a convenient option for obtaining these medications. Many synthetic hormones are prescription medications, and retail pharmacies are equipped to handle prescription-based dispensing. Healthcare providers often prescribe synthetic hormones to patients, who then rely on retail pharmacies to obtain their medications. Retail pharmacists play a crucial role in patient education. They can provide information about the proper use, dosage, potential side effects, and interactions of synthetic hormones, ensuring that patients understand how to take their medications safely and effectively. Retail pharmacies often work with various health insurance plans, which can cover a significant portion of the cost of synthetic hormone prescriptions. This can make obtaining synthetic hormones more affordable for patients, as insurance coverage reduces out-of-pocket expenses.

Download Free Sample Report

Regional Insights

The North America region emerged as the largest market in the Global Synthetic Hormones Market in 2024. North America, particularly the United States and Canada, has a significant and aging population. The aging demographic is more likely to require hormone replacement therapies and treatments for hormone-related conditions, such as menopause, hypothyroidism, and hormonal cancers. This creates a substantial demand for synthetic hormones. North America boasts a highly developed and technologically advanced healthcare infrastructure. This infrastructure supports the diagnosis and treatment of hormone-related disorders, including the prescription and administration of synthetic hormones. There is a high level of healthcare awareness in North America, leading to early diagnosis and treatment of hormone-related disorders. Increased awareness among both healthcare professionals and the general population contributes to the higher utilization of synthetic hormones.

Recent Developments

• In February 2022, The European Commission has approved the once-weekly injection of NGENLA (somatrogon), a next-generation long-acting recombinant human growth hormone, to treat children and adolescents from the age of three who have growth disturbances caused by insufficient growth hormone secretion. NGENLA offers paediatric kids with growth hormone deficiency (GHD), their carers, and healthcare professionals a novel therapy option that lowers the frequency of necessary injections from once daily to once weekly. NGENLA (somatrogon) is a synthetic growth hormone that works by replacing the lack of growth hormone in the body. NGENLA is taken by injection just below the skin. Compared to the growth hormone GENOTROPIN (somatropin), its action in the body lasts longer, enabling weekly injections instead of daily. GHD is a rare disease characterized by the inadequate secretion of the growth hormone, somatropin, from the pituitary gland and affects one in approximately 4,000 to 10,000 children worldwide. The disease can be caused by genetic mutations or acquired after birth. Without treatment, affected children will have persistent growth attenuation and a very short height in adulthood, and puberty may be delayed. Children may also experience other problems with physical health and mental well-being.
• In September 2021, Theramex has launched Bijuva / Bijuve across Europe and the UK. Bijuva, (known as Bijuve in the UK), is the first, and only, body-identical hormone therapy treatment (HRT) for estrogen deficiency symptoms in post-menopausal women with intact uterus and at least 12 months since last menses, which combines estradiol and progesterone in a single daily oral capsule. Unlike synthetic hormone products, the estradiol and progesterone found in Bijuva / Bijuve are chemically and biologically identical to the hormones naturally circulating in the woman’s body. The idea of using body identical hormones to replace estrogens and to protect the endometrium with progesterone appeals to many women. These hormones that many women prefer are now available in a combined single capsule that has been shown to be effective and well-tolerated.

Key Market Players

• Acerus Pharmaceuticals Corp.
• American Regent, Inc.
• Anhui Anke Biotechnology (Group) Co. Ltd.
• BioPartners, Inc
• Eli Lilly and Company
• Endo Pharmaceuticals, Inc.
• F. Hoffmann-La Roche Ltd.
• IBSA Institut Biochimique SA
• Lupin Pharmaceuticals, Inc.
• Pfizer, Inc

Report Scope:

In this report, the Global Synthetic Hormones Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

•     Synthetic Hormones Market, By Product:

o   Amino Acid Derivatives

o   Peptide Hormone

o   Steroid Hormones

•     Synthetic Hormones Market, By Route of Administration:

o   Intravenous

o   Nasal

o   Oral

o   Suppository

o   Topical

• Synthetic Hormones Market, By Application:

o   Growth Hormone Deficiency

o   Male Hypogonadism

o   Menopause

o   Thyroid Hormone Deficiency

•     Synthetic Hormones Market, By End-User:

o   Hospital Pharmacies

o   Online Pharmacies

o   Retail Pharmacies

• Synthetic Hormones Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Australia

§  Japan

o   Europe

§  Germany

§  France

§  United Kingdom

§  Spain

§  Italy

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Synthetic Hormones Market.

Available Customizations:

Global Synthetic Hormones Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).